Skip to main content

Sequenom Hopes to Net $28M From Private Stock Placement

NEW YORK (GenomeWeb News) — Sequenom said today it hopes to net $28 million in a private placement of 3.4 million shares of common stock at $9 apiece.   

The company said it plans to use the money to research, develop, and commercialize “various diagnostic tests,” and for general corporate purposes.

Sequenom also reaffirmed its full-year 2007 revenue guidance of $39 million to $41 million, which would be an increase of between 37 percent and 44 percent over 2006 revenues.

The company said Lehman Brothers and UBS Investment Bank were joint-lead placement agents in the private placement and Oppenheimer & Co., Leerink Swann, and Rodman & Renshaw were co-placement agents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.